Liver-protecting postbiotic composition and application thereof

Abstract

The invention discloses a liver-protecting postbiotic composition and application thereof, and belongs to the technical field of probiotics, and the liver-protecting postbiotic composition is an inactivated liver-protecting probiotic composition and a metabolite thereof; the liver-protecting probiotic composition is prepared from the following strains in parts by weight: 1 to 15 parts of animal bifidobacterium subsp. Lactis F1-7, 1 to 10 parts of animal bifidobacterium subsp. Lactis KV9, 5 to 25 parts of lactobacillus paracasei J5 and 10 to 40 parts of lactobacillus casei YRL577. According to the present invention, the matching of the bifidobacterium animalis subsp. Lactis F1-7, the bifidobacterium animalis subsp. Lactis KV9, the lactobacillus paracasei J5 and the lactobacillus casei YRL577 can regulate the liver metabolism, significantly reduce the fat accumulation in the liver, improve the antioxidant ability of the liver and protect the liver from being damaged, and the liver protection product has good liver function strengthening effect, and can be used for preparing the liver protection product. Especially, the traditional Chinese medicine composition has a relatively good treatment effect on non-alcoholic fatty liver.

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a liver-protecting postbiotic composition and application thereof. Background Art

[0002] The liver is the metabolic center of the three major nutrients of the human body, namely sugar, protein and fat, and is responsible for regulating various metabolic activities in the human body. As people's pace of life accelerates, the liver is overloaded every day. Coupled with bad living habits, such as lack of sleep, overeating, skipping breakfast, drug abuse, bad mood, excessive drinking, etc., the liver is often in a sub-healthy state. Over time, liver damage continues to accumulate and worsen, which can easily lead to illness and induce acute hepatitis, chronic hepatitis, alcoholic fatty liver, drug-induced hepatitis, alcoholic hepatitis, cirrhosis, liver failure, liver cancer, obesity and other diseases. Therefore, it is particularly important to strengthen the maintenance of the liver in daily life, repair liver damage in a timely and efficient manner, and enhance liver immunity.

[0003] At present, most of the liver protection products on the market are Western medicines. Although they have certain effects, they have side effects and indirectly harm the liver or other organs of the human body. They are not suitable for daily liver care as food. Therefore, it is very important to actively find food-grade, efficient, healthy and safe liver protection products.

[0004] More and more reports show that probiotics have good effects in nourishing and protecting the liver and alleviating liver damage, such as CN117467561A, CN118853462A and CN113337430A, but no research has been found on the combined liver protection of Bifidobacterium animalis subsp. lactis, Lactobacillus paracasei and Lactobacillus casei. Summary of the invention

[0005] The purpose of the present invention is to provide a liver-protecting postbiotic composition and an application thereof. The liver-protecting postbiotic composition of the present invention utilizes the enhanced combination of animal Bifidobacterium lactis subsp. lactis, Lactobacillus paracasei and Lactobacillus casei to achieve the effects of improving liver metabolic function, reducing liver damage and improving fatty liver.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions: In a first aspect, the present invention provides a liver-protecting probiotic composition, which is composed of Bifidobacterium animalis subsp. lactis, Lactobacillus paracasei and Lactobacillus casei. Wherein, the Bifidobacterium animalis lactis subspecies is Bifidobacterium animalis lactis subspecies F1-7 and Bifidobacterium animalis lactis subspecies KV9, the Lactobacillus paracasei is Lactobacillus paracasei J5; and the Lactobacillus casei is Lactobacillus casei YRL577.

[0007] Animal Bifidobacterium lactis subspecies F1-7 can promote the balance of liver cholesterol metabolism, reduce cholesterol deposition in liver cells, and maintain liver lipid homeostasis; prevent fatty degeneration of liver cells, protect the liver from fat infiltration, and maintain normal physiological function of the liver; reduce the oxidative stress response of the liver, inhibit the lipid peroxidation process, and protect the integrity of liver cells; provide liver protection, prevent and improve liver function damage, and maintain the healthy state of the liver.

[0008] Animal Bifidobacterium lactis subspecies KV9 can enhance the activity of key liver enzymes - alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), optimize the liver metabolic pathway, reduce the accumulation of harmful intermediates, and strengthen protection of the liver; reduce the concentration of toxic substances, promote healthy liver metabolism, and reduce potential liver cell damage; shorten the time of physical discomfort caused by adverse metabolic substances, and comprehensively protect liver health.

[0009] Lactobacillus paracasei J5 can increase the liver's antioxidant capacity, improve liver lipid accumulation, and alleviate liver damage.

[0010] Lactobacillus casei YRL577 promotes liver lipid metabolism, inhibits liver fat accumulation, and relieves fatty liver by activating the farnesol receptor; it has a high BSH (bile salt hydrolase) activity; it reduces liver weight and liver index, and can regulate lipid metabolism, oxidative stress, and pro-inflammatory cytokine levels; it regulates genes in the intestinal bile acid pathway, which helps to relieve fatty liver.

[0011] Experiments have shown that the combination of animal Bifidobacterium lactis subspecies F1-7, animal Bifidobacterium lactis subspecies KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577 can significantly improve the liver's antioxidant capacity and reduce liver damage, especially non-alcoholic liver damage.

[0012] Preferably, the liver-protecting probiotic composition consists of the following strains by weight: 1-15 parts of Bifidobacterium animalis subspecies lactis F1-7, 1-10 parts of Bifidobacterium animalis subspecies lactis KV9, 5-25 parts of Lactobacillus paracasei J5 and 10-40 parts of Lactobacillus casei YRL577.

[0013] Further preferably, the liver protecting probiotic composition consists of the following strains by weight: 3-15 parts of Bifidobacterium animalis subspecies lactis F1-7, 2-10 parts of Bifidobacterium animalis subspecies lactis KV9, 10-25 parts of Lactobacillus paracasei J5 and 15-40 parts of Lactobacillus casei YRL577.

[0014] More preferably, the liver protecting probiotic composition consists of the following strains by weight: 10 parts of Bifidobacterium animalis subspecies lactis F1-7, 5 parts of Bifidobacterium animalis subspecies lactis KV9, 15 parts of Lactobacillus paracasei J5 and 25 parts of Lactobacillus casei YRL577.

[0015] In a second aspect, the present invention provides a method for preparing the above-mentioned liver-protecting probiotic composition, comprising the following steps: mixing Bifidobacterium animalis subspecies lactis F1-7, Bifidobacterium animalis subspecies lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577.

[0016] In a third aspect, the present invention provides a liver-protecting postbiotic composition, comprising the aforementioned inactivated liver-protecting probiotic composition and its metabolites.

[0017] In a fourth aspect, the present invention also provides a method for preparing the above-mentioned liver-protecting postbiotic composition, comprising the following steps: (1) Cultivation of Bifidobacterium animalis subsp. lactis F1-7, Bifidobacterium animalis subsp. lactis KV9, Lactobacillus paracasei J5, and Lactobacillus casei YRL577; (2) inactivation step (1) of Bifidobacterium animalis subsp. lactis F1-7, Bifidobacterium animalis subsp. lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577 cultured; (3) Evenly mix the inactivated Bifidobacterium animalis subspecies lactis F1-7, Bifidobacterium animalis subspecies lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577 in step (2).

[0018] Preferably, the culture in step (1) is the culture of Bifidobacterium animalis subsp. lactis F1-7, Bifidobacterium animalis subsp. lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577, respectively, or any mixed culture of at least two or more thereof.

[0019] Preferably, the inactivation in step (2) is to inactivate the Bifidobacterium animalis subsp. lactis F1-7, Bifidobacterium animalis subsp. lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577 cultured separately or to inactivate them after mixing.

[0020] In a fifth aspect, the present invention provides the use of the above-mentioned liver protecting probiotic composition or liver protecting postbiotic composition in the preparation of liver protecting products.

[0021] Preferably, the liver protection is to improve the liver's antioxidant capacity, reduce liver fat accumulation, reduce total cholesterol and triglyceride content in the liver, and treat non-alcoholic fatty liver disease; more preferably, it is to treat non-alcoholic fatty liver disease.

[0022] Preferably, the product is a dietary supplement, a food, a health product or a medicine.

[0023] In a sixth aspect, the present invention provides a liver protection product comprising the aforementioned liver protection composition or liver protection postbiotic composition and acceptable excipients.

[0024] Preferably, the liver protection product is in the form of granules, powder, blocks, paste or liquid.

[0025] The beneficial effects of the present invention are: (1) The present invention found that the combination of Bifidobacterium animalis subsp. lactis F1-7, Bifidobacterium animalis subsp. lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577 can regulate liver metabolism, significantly reduce fat accumulation in the liver, improve the liver's antioxidant capacity, and protect the liver from damage. (2) Compared with existing liver-protecting probiotics or postbiotics, the dosage of the present invention is smaller and the liver-protecting effect is better.

[0026] (3) The present invention provides a combined use of Bifidobacterium animalis subsp. lactis F1-7, Bifidobacterium animalis subsp. lactis KV9, Lactobacillus paracasei J5, and Lactobacillus casei YRL577 in the preparation of a liver protection product. The product prepared by the present invention can regulate liver metabolism, significantly reduce fat accumulation in the liver, improve the liver's antioxidant capacity, protect the liver from damage, and has a good effect of strengthening liver function, especially has a good therapeutic effect on non-alcoholic fatty liver disease.

[0027] (4) The liver-protecting probiotic composition and the liver-protecting postbiotic composition of the present invention are safe, have no toxic side effects, and are suitable for long-term use. DETAILED DESCRIPTION

[0028] The following examples are only used to help understand the method of the present invention and its core idea. It should be noted that for those of ordinary skill in the art, without departing from the principles of the present invention, the present invention may also be subjected to several improvements and modifications, which also fall within the scope of protection of the claims of the present invention. The following description of the disclosed embodiments enables professionals and technicians in this field to implement or use the present invention. It will be apparent to professionals and technicians in this field that various modifications to these embodiments, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to these embodiments shown herein, but may be applied to a wider range consistent with the principles and novel features disclosed herein. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs.

[0029] The "acceptable excipients" described in the present invention include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients, colorants, coating agents, sweeteners and flavoring agents may also be present in the composition.

[0030] The present invention does not limit the sources of the raw materials used. Unless otherwise specified, the raw materials used in the present invention are all common commercial products in the technical field. It is worth noting that the probiotics used in the present invention are bacterial powders, all of which are purchased from Zhongchuang Yi Ke. The specific information is shown in Table 1 below.

[0031] Table 1 Raw material information

[0032] Liver protection postbiotic composition of Examples 1-4 and Comparative Examples 1-3 The liver-protecting postbiotic compositions of different embodiments and comparative examples were prepared according to Table 2 and the following preparation methods.

[0033] Preparation method: Mix the formulated amounts of Bifidobacterium animalis subspecies F1-7, Bifidobacterium animalis subspecies KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577, and inactivate them.

[0034] Table 2 Formulas of liver-protecting postbiotic compositions of Examples and Comparative Examples (Unit: weight parts)

[0035] Remark: 1. The “-” in the table means not added; 2. The preparation method of Comparative Example 1 is as follows: mixed the formulated amounts of Bifidobacterium animalis subspecies lactis F1-7, Bifidobacterium animalis subspecies lactis KV9 and Lactobacillus casei YRL577, and inactivated them.

[0036] 3. The preparation method of Comparative Example 2 is as follows: inactivating the formulated amount of Lactobacillus paracasei J5.

[0037] Effect example: Effect of liver-protecting postbiotic composition on non-alcoholic fatty liver disease 1. Experimental Animals C57BL / 6J mice, male, weighing 18-20 g.

[0038] 2. Experimental methods After 1 week of adaptive feeding, the mice were randomly divided into 10 groups according to their body weight, with 8 mice in each group. Specifically: (1) Normal control group: fed with normal diet for 12 weeks and gavaged with normal saline; (2) Model group: fed with a high-fat diet for 12 weeks and gavaged with normal saline; (3) Experimental groups: divided into experimental groups S1 to S4 and experimental groups D1 to D3. The experimental groups were fed with a high-fat diet for 12 weeks and gavaged with the liver-protecting postbiotic compositions prepared in Examples 1 to 4 and Comparative Examples 1 to 3; (4) Positive control group: fed with a high-fat diet for 12 weeks and given orlistat by gavage.

[0039] 3. Detection indicators After the last oral administration, the mice were fasted for 12 h, killed by cervical dislocation, and their livers were removed and weighed.

[0040] Take 1g of liver, add appropriate amount of physiological saline, and fully homogenize to prepare 10% liver homogenate. Centrifuge at 3000 r / min for 10 minutes at low temperature (temperature 4°C), take the supernatant, and use ELISA kit to detect the content of total cholesterol (TG) and triglyceride (TC) in the liver.

[0041] Grind 1 g of liver and centrifuge it at 3000 r / min for 20 minutes at low temperature (4°C). Take the supernatant and use a kit to detect the activity of glutathione peroxidase (GSH-Px). At the same time, detect the level of lipid peroxidation product malondialdehyde (MDA) to indirectly judge the severity of free radical attack on cells.

[0042] 4. Results 1. Liver weight The results are shown in Table 3.

[0043] Table 3 Mouse liver weight (g)

[0044] Note: Different letters in the same column in the table indicate that the data between groups are significantly different, P < 0.05.

[0045] The results show: Compared with the normal control group, the liver weight of the model group mice increased significantly after being fed a high-fat diet for 12 weeks (P < 0.05), indicating that a high-fat diet can cause non-alcoholic liver weight gain.

[0046] Compared with the model group, the liver weights of mice in the positive control group and each experimental group were significantly reduced (P < 0.05), indicating that the liver-protecting postbiotic compositions provided by the positive drug, Examples 1-4 and Comparative Examples 1-3 all have the effect of reducing non-alcoholic liver weight gain caused by a high-fat diet, and can alleviate non-alcoholic fatty liver disease by reducing liver fat accumulation, thereby exerting a liver-protecting effect.

[0047] Comparison of the positive control group and the experimental group shows that the liver protection postbiotic composition provided by Examples 1 to 4 of the present invention is equivalent to orlistat in reducing non-alcoholic liver weight gain. The liver protection postbiotic composition provided by Comparative Examples 1 to 3 is significantly inferior to Examples 1 to 4 in reducing non-alcoholic liver weight gain.

[0048] 2. Content of total cholesterol (TG) and triglycerides (TC) in the liver The results are shown in Table 4.

[0049] Table 4 Contents of total cholesterol (TG) and triglyceride (TC) in mouse liver

[0050] Note: Different letters in the same column in the table indicate that the data between groups are significantly different, P < 0.05.

[0051] The results show: Compared with the normal control group, after 12 weeks of feeding with a high-fat diet, the levels of total cholesterol (TG) and triglycerides (TC) in the liver of the model group mice increased significantly (P < 0.05), indicating that a high-fat diet can cause an increase in the levels of total cholesterol (TG) and triglycerides (TC) in the liver.

[0052] Compared with the model group, the contents of total cholesterol (TG) and triglyceride (TC) in the liver of mice in the positive control group and experimental groups S1-S4 were significantly reduced (P < 0.05), and there was no statistical difference in the contents of total cholesterol (TG) and triglyceride (TC) in the liver of mice in experimental groups S1-S4 compared with the positive control group (P > 0.05). This shows that the liver-protecting postbiotic composition provided by Examples 1-4 of the present invention can reduce the levels of total cholesterol (TG) and triglyceride (TC) in the liver, and is equivalent to orlistat.

[0053] At the same time, by comparing the experimental groups S1 to S4 and the experimental groups D1 to D3, it can be seen that the liver-protecting postbiotic compositions provided by comparative examples 1 to 3 are significantly inferior to those of examples 1 to 4 in reducing the content of total cholesterol (TG) and triglycerides (TC) in the liver and reducing fat accumulation in the liver.

[0054] 3. Antioxidant activity of liver lipids in the liver The results are shown in Table 5.

[0055] Table 5 GSH-Px and MDA contents in mouse liver

[0056] Note: Different letters in the same column in the table indicate that the data between groups are significantly different, P < 0.05.

[0057] The results show: Compared with the normal control group, after 12 weeks of feeding with a high-fat diet, the activity of glutathione peroxidase in the liver of the model group mice was significantly decreased (P < 0.05), and the level of peroxidation product malondialdehyde was significantly increased (P < 0.05).

[0058] Compared with the model group, the activity of glutathione peroxidase and the level of peroxidation product malondialdehyde in the liver of mice in the positive control group and each experimental group were significantly different (P < 0.05), indicating that the positive drug and the liver-protecting postbiotic composition administered by gavage in each experimental group can improve the liver antioxidant activity of mice.

[0059] It can be found from the positive control group and each experimental group that the liver-protecting postbiotic composition provided by Examples 1 to 4 of the present invention has better liver antioxidant activity than the positive drug and the liver-protecting postbiotic composition provided by Comparative Examples 1 to 3.

[0060] The above is a further description of the present invention in conjunction with specific embodiments, but these embodiments are merely exemplary and do not constitute any limitation on the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

Claims

1. A liver-protecting postbiotic composition, characterized in that: It is an inactivated liver-protecting probiotic composition and its metabolites; The liver-protecting probiotic composition consists of the following strains by weight: 1-15 parts of animal Bifidobacterium lactis subspecies F1-7, 1-10 parts of animal Bifidobacterium lactis subspecies KV9, 5-25 parts of Lactobacillus paracasei J5 and 10-40 parts of Lactobacillus casei YRL577.

2. The liver-protecting postbiotic composition according to claim 1, characterized in that: The liver-protecting probiotic composition consists of the following strains by weight: 3-15 parts of animal bifidobacterium lactis subspecies F1-7, 10 parts of animal bifidobacterium lactis subspecies KV92, 10-25 parts of Lactobacillus paracasei J5 and 15-40 parts of Lactobacillus casei YRL577.

3. The liver-protecting postbiotic composition according to claim 1, characterized in that The liver-protecting probiotic composition consists of the following strains by weight: 10 parts of animal Bifidobacterium lactis subspecies F1-7, 5 parts of animal Bifidobacterium lactis subspecies KV9, 15 parts of Lactobacillus paracasei J5 and 25 parts of Lactobacillus casei YRL577.

4. The liver-protecting postbiotic composition according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: mixing Bifidobacterium animalis subspecies lactis F1-7, Bifidobacterium animalis subspecies lactis KV9, Lactobacillus paracasei J5 and Lactobacillus casei YRL577.

5. The liver-protecting postbiotic composition according to any one of claims 1 to 3, characterized in that: The preparation method comprises inactivating the liver-protecting probiotic composition.

6. Use of the liver protection postbiotic composition according to any one of claims 1 to 5 in the preparation of liver protection products.

7. The use according to claim 6, characterized in that: The liver protection is to improve the liver's antioxidant capacity, reduce liver fat accumulation, treat non-alcoholic fatty liver, and reduce the total cholesterol and triglyceride content in the liver.

8. The use according to claim 6, characterized in that: The product is a dietary supplement, food, health product or medicine.

9. The use according to claim 6, characterized in that: The liver protection product comprises the liver protection postbiotic composition and acceptable auxiliary materials.

10. The use according to claim 6, characterized in that: The liver protection product is in the form of granules, powder, blocks, paste or liquid.

Images